Mimetogen Pharmaceuticals

8 articles about Mimetogen Pharmaceuticals

• Mimetogen Pharmaceuticals Completes Enrollment of MIM-728 Phase 3 Trial for Tavilermide for Dry Eye Disease

  3/31/2020

  Mimetogen Pharmaceuticals Inc. (“Mimetogen”), a clinical-stage biopharmaceutical company focused on the development of tavilermide, a first-in-class nerve growth factor (NGF) mimetic for the treatment of dry eye disease, today announced that it completed enrollment of its 600-patient MIM-728 Phase 3 clinical trial for tavilermide ophthalmic solution.

• Allergan Pays $50 Million Upfront to Mimetogen for Dry Eye Disease Development Pact

  11/4/2015

• Mimetogen Pharmaceuticals Announces Expiration Of Exclusive Option Agreement With Bausch & Lomb

  9/11/2014

• Mimetogen Pharmaceuticals Announces Topline Results Of Its Second Clinical Study With MIM-D3 For The Treatment Of Dry Eye Syndrome

  9/9/2014

• Mimetogen Pharmaceuticals Appoints Kim Brazzell, Ph.D. as Chief Medical Officer

  1/5/2012

• Mimetogen Pharmaceuticals Announces Positive Top Line Data from Phase II Clinical Trial of MIM-D3 for Dry Eye Disease

  6/27/2011

• Mimetogen Pharmaceuticals Announces Positive Top Line Data from Phase II Clinical Trial of MIM-D3 for Dry Eye Disease

  6/27/2011

• Mimetogen Pharmaceuticals Completes Key Equity Financing for Ophthalmology Drugs

  10/7/2009